Roy S. Herbst, MD, PhD is Deputy Director for Yale Cancer Center and Chief of Medical Oncology for Yale Cancer Center and Smilow Cancer Hospital. He is Ensign Professor of Medicine at Yale School of Medicine. He is a fellow of the American Society of Clinical Oncology and the American College of Physicians, an elected member of the Association of American Physicians, and an elected member of the boards of directors for both AACR and the IASLC.

Dr. Herbst is a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments to patients, serving as principal investigator for trials leading to approval of several therapies revolutionizing the field and greatly enhancing patients’ lives. He has more than 300 publications to his name, and his work published in Nature was awarded Clinical Research Forum’s 2015 Herbert Pardes Clinical Research Excellence Award.

The NCI Lung SPORE Dr. Herbst leads has identified new mechanisms of sensitivity and resistance to immunotherapy. His work on “umbrella” trials, such as Lung MAP, has galvanized the field by developing public-private partnerships to conduct large clinical studies. He is a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings, and he chairs the American Association of Cancer Research’s Tobacco Task Force.

For his lifetime of achievement in thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at their World Conference on Lung Cancer in Vienna, Austria.